+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes



Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes



Vaccine 23(25): 3264-3271



Pseudomonas aeruginosa is a serious human pathogen in a variety of patient groups including those with burns, hospitalized in intensive care, cystic fibrosis and neutropenia. Since there is no vaccine available, passive antibody prophylaxis against protective epitopes is an alternative strategy to prevent P. aeruginosa infection. However, immunoglobulin derived from multiple donors has variable anti-pseudomonas antibody titers, and human Mab are difficult to make from patient samples. We previously reported the use of XenoMouse mice, Ig-inactivated transgenic mice reconstituted with human immunoglobulin loci, to generate human Mab against a single serotype of P. aeruginosa lipopolysaccharide O-specific side chain (PS). We now report the creation of a panel of anti-PS human IgG2 Mab against nine additional O-specific side chain P. aeruginosa serotypes. The majority of the Mab were highly opsonic for uptake and killing of homologous P. aeruginosa by human PMN in the presence of human complement, and all the Mab protected cyclophosphamide-induced neutropenic mice from fatal P. aeruginosa sepsis with homologous serotypes. DNA sequence analysis showed that the Mab used V(H)3, V(H)4, V(H)5 and V(H)6 and Vkappa2, 3 and 4 variable region genes consistent with the heterogeneity of P. aeruginosa LPS O-side chain structure. We conclude that human Mab made in these transgenic mice against common pathogenic serotypes of P. aeruginosa are opsonic and highly protective, and that a high titer, multi-valent human Mab preparation against the majority of circulating O-side chain serotypes of P. aeruginosa could be used as prophylaxis against invasive infections in selected patient groups.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012331109

Download citation: RISBibTeXText

PMID: 15837231

DOI: 10.1016/j.vaccine.2005.01.088


Related references

Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infection and Immunity 69(4): 2223-2229, 2001

Human monoclonal antibody against Pseudomonas aeruginosa LPS derived from transgenic XenoMouseTM mice is opsonic and highly protective in the neutropenic mouse model of sepis. Clinical Infectious Diseases 31(1): 213, 2000

Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice. Clinical and Diagnostic Laboratory Immunology 6(4): 537-541, 1999

Effect of human monoclonal antibody against O-antigen and core-antigen of lipopolysaccharide on gut-derived Pseudomonas aeruginosa sepsis in mice. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 66, 2003

Comparison of pre- versus post-sepsis treatment with polyclonal immunoglobulin versus O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice. Serodiagnosis and ImmunoTherapy in Infectious Disease 4(3): 221-230, 1990

Immunoprophylaxis of pseudomonas aeruginosa burn wound sepsis with a cross reactive human monoclonal antibody. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 126, 1988

Opsonic killing and mouse protective activity of monoclonal mab and polyclonal human immunoglobulin g m and a specific for pseudomonas aeruginosa lipopolysaccharide lps. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 49, 1988

A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infection and Immunity 59(1): 1-6, 1991

Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection. Infection and Immunity 76(10): 4720-4725, 2008

Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrobial Agents and ChemoTherapy 53(8): 3442-3446, 2009

Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrobial Agents and ChemoTherapy 42(11): 2853-2857, 1998

Effect of Interleukin-10 on Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice. Antimicrobial Agents and Chemotherapy 42(11): 2853-2857, 1998

Protection studies in a mouse burn wound sepsis model with a human anti pseudomonas aeruginosa flagella monoclonal antibody and its fab 2 and fab fragments. Abstracts of the Annual Meeting of the American Society for Microbiology 90: 123, 1990

Protection against pseudomonas aeruginosa pa sepsis in burned mice with cross reactive monoclonal antibody mca. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 49, 1988

Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice. Zentralblatt für Bakteriologie Mikrobiologie und Hygiene. 1. Abt. Originale A Medizinische Mikrobiologie Infektionskrankheiten und Parasitologie 252(3): 370-383, 1982